title: Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects.
abstract: OBJECTIVE
  The objective of this study was to examine the pharmacokinetics and the tolerability/safety of mirtazapine and cimetidine separately and in combination following oral administration of multiple doses.
  
  
  METHODS
  This was a double-blind, placebo-controlled, two-period cross-over, multiple-dose pharmacokinetic interaction study in 12 healthy male subjects. They received either cimetidine (800 mg b.i.d.) or placebo in combination with (commercially available, racemic) mirtazapine (30 mg nocte). Cimetidine and placebo were administered for 14 days, with mirtazapine added during days 6-12 of each period. Serial blood samples for kinetic profiling were taken on day 5 and day 12 for cimetidine and on days 12-14 for mirtazapine.
  
  
  RESULTS
  The co-administration of cimetidine resulted in a statistically significant increase in the area under the curve (AUC(0-24)) and Cmax of mirtazapine (54% and 22% respectively). The AUC(0-24) of demethylmirtazapine increased only slightly, and there was no effect on Cmax. The elimination half-lives for both mirtazapine and its demethyl metabolite were unaffected by cimetidine co-administration. The trough and average plasma concentrations during the steady state were elevated during cimetidine treatment (62% and 54%, respectively). Mirtazapine had no effect on the pharmacokinetics of cimetidine.
  
  
  CONCLUSIONS
  Co-administration of cimetidine (800 mg b.i.d.) and mirtazapine (30 mg nocte) resulted in increased steady-state plasma levels of mirtazapine (C(ss,min) = +61%, P < 0.05; C(ss,av) = +54%, P < 0.05), probably as a result of increased bio-availability. The Cmax (+22%, P < 0.05) and AUC(0-24) (+54%, P < 0.05) also increased. Due to the variability of the mirtazapine plasma levels in patients, the clinical meaning of these increases is probably limited. Co-administration of mirtazapine did not alter cimetidine pharmacokinetics.
authors.affiliation: N.V. Organon, Oss, The Netherlands. j.sitsen@organon.oss.akzonobel.nl
authors.forename: J M
authors.initials: JM
authors.lastname: Sitsen
authors.forename: F A
authors.initials: FA
authors.lastname: Maris
authors.forename: C J
authors.initials: CJ
authors.lastname: Timmer
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002927:Cimetidine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004347:Drug Interactions; D006207:Half-Life; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008803:Mianserin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008875:Middle Aged; D000078785:Mirtazapine
chemical_list: D000929:Antidepressive Agents, Tricyclic; D006635:Histamine H2 Antagonists; D008803:Mianserin; D002927:Cimetidine; D000078785:Mirtazapine